

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Peter Emig et al.

GAU 1624

Examiner Kahsay Habte

Serial No. 09/910,141

Filed on July 10, 2001

For: NOVEL HETEROARYL DERIVATIVES, etc.

Attorney's Docket 0691-070

Commissioner of Patents
Washington DC 20231

Sir:

Information Disclosure Statement

Enclosed herewith is an Information Disclosure Statement Form, together with a copy of each of the references identified therein.


WO 99/16751 relates to benzamidine derivatives for inhibiting the Xa coagulation factor for treatment and prophylaxis of thromboembolytic diseases.

European patent No. 112,776 relates to naphthalene and azanaphthalenecarboxamide derivatives and methods for making.

European patent No. 831,090 relates to N-substituted cyclic amines, methods for making, and compositions containing them.


Respectfully submitted

Customer No. address 23622



Gabriel R. Katona, attorney of record

It is hereby certified that this is being mailed on November 13, 2002



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/910,141
		Filing Date	July 10, 2001
		First Named Inventor	Peter Ernio et al.
		Art Unit	1624
		Examiner Name	Kahsay Habte
		Attorney Docket Number	0691-070
Sheet	1	of	2

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number- Kind Code ² (if known)			
		US- 5,432,175	07-11-1995	Piwnski et al.	
		US- 5,861,395	01-19-1999	Taveras et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ , Kind Code ⁵ (if known)			
		WO	97/44329	11-27-1997		
		WO	99/16751	04-08-1999		
		WO	00/12074	03-09-2000		
		WO	00/51614	09-08-2000		
		EP	0 112 776 A2	07-04-1984		
		EP	0 831 090 A1	03-25-1998		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

control number. Substitute for form 1449B/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(use as many sheets as necessary)</i></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;">Sheet</td> <td style="width: 15%; text-align: center;">2</td> <td style="width: 15%;">of</td> <td style="width: 15%; text-align: center;">2</td> </tr> </table>		Sheet	2	of	2	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; padding: 5px;"><i>Complete if Known</i></th> </tr> <tr> <td style="width: 60%;">Application Number</td> <td>09/910.141</td> </tr> <tr> <td>Filing Date</td> <td>July 10, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Peter Emla et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>1624</td> </tr> <tr> <td>Examiner Name</td> <td>Kahsay Habte</td> </tr> <tr> <td>Attorney Docket Number</td> <td>0691-070</td> </tr> </table>		<i>Complete if Known</i>		Application Number	09/910.141	Filing Date	July 10, 2001	First Named Inventor	Peter Emla et al.	Group Art Unit	1624	Examiner Name	Kahsay Habte	Attorney Docket Number	0691-070
Sheet	2	of	2																		
<i>Complete if Known</i>																					
Application Number	09/910.141																				
Filing Date	July 10, 2001																				
First Named Inventor	Peter Emla et al.																				
Group Art Unit	1624																				
Examiner Name	Kahsay Habte																				
Attorney Docket Number	0691-070																				

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/910.141
		Filing Date	July 10, 2001
		First Named Inventor	Peter Emia et al.
		Group Art Unit	1624
		Examiner Name	Kahsay Habte
Sheet 2 of 2	Attorney Docket Number	0691-070	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
K1		TODD R. ELWORTHY, ANTHONY P.D.W. FORD, GARY W. BANTLE, et al., N-Arylpiperazinyl-N'-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α 1-Adrenoceptor Antagonists, J. Med. Chem. 1997, 40, 2674-2687	
K1		ARTHUR G. TAVERAS, JEFF DESKUS, JIANPING CHAO, CYNTHIA J. CACCARO, et al., Identification of Pharmacokinetically Stable 3,10-Dibromo-8-chlorobenzocycloheptapyridine Farnesyl Protein Transferase Inhibitors with Potent Enzyme and Cellular Activities, J. Med Chem. 1999, 42, 2651-2661	
K1		EL-SEBAI A. IBRAHIM, I. CHAABAN and S. M. EL-KHAWASS, Synthesis of Some Quinoline Derivatives of Potential Antiamebic Activity, Pharmazie 32, H. 3 (1977), 155-156	
<p>RECEIVED</p> <p>NOV 20 2002</p> <p>TECH CENTER 1600/2900</p>			

Examiner Signature	<i>At Khay [Signature]</i>	Date Considered	June 18, 2003
--------------------	----------------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.